United Therapeutics Corp

Company Profile

• Business description

  United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

• Contact

  1000 Spring Street
  Silver SpringMD20910
  USA

  T: +1 301 608-9292

  E: [email protected]

  https://www.unither.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Drug Manufacturers - Specialty & Generic

  Fiscal Year End

  31 December 2025

  Employees

  1,305